Wockhardt's Q3 FY26 Revenue Surges 22%, EBITDA Grows 72%

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported a robust Q3 FY26 performance with a 22% year-over-year growth in revenue and a 72% growth in EBITDA. The Innovative portfolio contributed 26.3% of the Q3FY26 revenue. The Biotech business grew by 96% in Q4FY25 and 38% in Q2FY26, driven by the Emerging Market biotech segment and strategic business partnerships. The India Branded Business and UK region also reported growth. The company has a strong pipeline with 7 biosimilars, 11 filings, and 11 approvals, and 2 NCE filings with 1 approval. The Novel Antibiotics portfolio also reported key updates.